Nuvation Bio Performance dei guadagni passati
Il passato criteri di controllo 0/6
Nuvation Bio's earnings have been declining at an average annual rate of -43.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 171.4% per year.
Informazioni chiave
-43.1%
Tasso di crescita degli utili
-31.9%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 6.0% |
| Tasso di crescita dei ricavi | 171.4% |
| Rendimento del capitale proprio | -96.0% |
| Margine netto | -35,590.2% |
| Ultimo aggiornamento sui guadagni | 30 Jun 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Nuvation Bio: Competitive Data In ROS1+ NSCLC, Strong Cash, Smallish Market
Oct 21Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024
Aug 08Is Nuvation Bio (NYSE:NUVB) A Risky Investment?
Aug 07
Nuvation Bio: A Potentially Transformative Acquisition
Jun 20Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Ripartizione dei ricavi e delle spese
Come Nuvation Bio guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -511 | 37 | 501 |
| 31 Mar 24 | 0 | -69 | 28 | 65 |
| 31 Dec 23 | 0 | -76 | 29 | 71 |
| 30 Sep 23 | 0 | -83 | 30 | 66 |
| 30 Jun 23 | 0 | -90 | 31 | 76 |
| 31 Mar 23 | 0 | -105 | 32 | 86 |
| 31 Dec 22 | 0 | -104 | 32 | 88 |
| 30 Sep 22 | 0 | -108 | 32 | 89 |
| 30 Jun 22 | 0 | -103 | 30 | 85 |
| 31 Mar 22 | 0 | -88 | 27 | 70 |
| 31 Dec 21 | 0 | -87 | 24 | 65 |
| 30 Sep 21 | 0 | -75 | 21 | 56 |
| 30 Jun 21 | 0 | -64 | 18 | 48 |
| 31 Mar 21 | 0 | -53 | 14 | 41 |
| 31 Dec 20 | 0 | -42 | 11 | 33 |
| 30 Sep 20 | 0 | -38 | 8 | 32 |
| 30 Jun 20 | 0 | -32 | 7 | 27 |
| 31 Mar 20 | 0 | -33 | 7 | 26 |
| 31 Dec 19 | 0 | -34 | 7 | 25 |
Guadagni di qualità: NUVB is currently unprofitable.
Margine di profitto in crescita: NUVB is currently unprofitable.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: NUVB is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.
Accelerare la crescita: Unable to compare NUVB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Guadagni vs Settore: NUVB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendimento del capitale proprio
ROE elevato: NUVB has a negative Return on Equity (-95.98%), as it is currently unprofitable.